Fibrocell Science, Inc.
(NASDAQ : FCSC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 1.46%243.821.3%$795.90m
IMMUImmunomedics, Inc. 0.07%85.3611.0%$697.18m
MRNAModerna, Inc. 6.60%69.470.0%$666.49m
NVAXNovavax, Inc. 10.86%113.5696.5%$629.01m
ILMNIllumina, Inc. 4.74%299.893.5%$582.79m
GILDGilead Sciences, Inc. 0.00%62.251.0%$574.11m
REGNRegeneron Pharmaceuticals, Inc. 2.98%574.062.7%$443.39m
VRTXVertex Pharmaceuticals, Inc. 1.92%268.181.9%$340.86m
BIIBBiogen, Inc. 1.20%273.281.6%$334.97m
ALXNAlexion Pharmaceuticals, Inc. 2.15%114.432.0%$285.22m
EXASEXACT Sciences Corp. 3.60%97.7020.7%$257.29m
SRNESorrento Therapeutics, Inc. 4.84%9.641.5%$240.99m
VXRTVaxart, Inc. 7.40%7.400.0%$213.88m
SGENSeattle Genetics, Inc. 3.08%184.956.0%$212.14m
MNTAMomenta Pharmaceuticals, Inc. 0.02%52.403.0%$193.58m

Company Profile

Fibrocell Science, Inc., is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. The fibroblast cell plays a key role in the production of collagen and growth factors which support the skin and other soft tissues; therefore, these cells could play a key role in treating many medical conditions. They have a robust pipeline and clinical programs based on the autologous fibroblast cell. They believe their aesthetic indication is a beachhead for higher value indications. They have a strong base of knowledge and expertise in cell based product development, manufacturing and seeking regulatory approvals. Their focus is to enter clinical programs to treat medical conditions that have an unmet need, helping patients and creating more value per cell.